|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:accessories
|
local distributors
|
|
gptkbp:acquired
|
Guangzhou Pharmaceutical Holdings Limited
|
|
gptkbp:acquisition
|
China National Pharmaceutical Group in 2016
|
|
gptkbp:advocacy
|
public awareness campaigns
|
|
gptkbp:allies
|
other pharmaceutical companies
|
|
gptkbp:benefits
|
comprehensive packages
|
|
gptkbp:ceo
|
Liang Zhiqiang
|
|
gptkbp:clinical_trial
|
vaccine efficacy
shared with regulatory bodies
various vaccines
|
|
gptkbp:collaboration
|
research projects
international health organizations
|
|
gptkbp:community_engagement
|
health initiatives
|
|
gptkbp:community_health
|
vaccination campaigns
various initiatives
|
|
gptkbp:community_outreach
|
health education programs
|
|
gptkbp:distribution_channels
|
national and international
|
|
gptkbp:economic_impact
|
international markets
|
|
gptkbp:employees
|
over 30,000
|
|
gptkbp:financial_performance
|
strong growth
|
|
gptkbp:financial_reports
|
published annually
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:global_presence
|
Asia, Africa, Europe
|
|
gptkbp:governance
|
transparent practices
|
|
gptkbp:headquarters
|
gptkb:Beijing,_China
|
|
gptkbp:healthcare
|
new technologies
high standards
integrated services
improved in rural areas
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm Group Holdings
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:innovation
|
new drug development
|
|
gptkbp:investment
|
healthcare sector
|
|
gptkbp:investment_in_research
|
gptkb:biotechnology
|
|
gptkbp:is_vulnerable_to
|
gptkb:vaccine
global supply chains
ongoing studies
|
|
gptkbp:market
|
pharmaceutical trends
|
|
gptkbp:market_cap
|
over 200 billion CNY
|
|
gptkbp:market_share
|
significant in China
|
|
gptkbp:operates_in
|
gptkb:China
|
|
gptkbp:parent_company
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:partnership
|
gptkb:World_Health_Organization
|
|
gptkbp:partnerships
|
government agencies
academic institutions
|
|
gptkbp:pharmaceutical_distribution
|
nationally and internationally
|
|
gptkbp:pharmaceutical_research
|
new therapies
|
|
gptkbp:portfolio_company
|
diverse pharmaceutical products
|
|
gptkbp:product
|
new vaccines
|
|
gptkbp:production_location
|
multiple locations in China
|
|
gptkbp:products
|
vaccines
|
|
gptkbp:provides_guidance_on
|
developed for vaccines
|
|
gptkbp:regulatory_compliance
|
gptkb:various_countries
strict adherence
|
|
gptkbp:research_and_development
|
biopharmaceuticals
|
|
gptkbp:revenue
|
over 100 billion CNY
|
|
gptkbp:safety
|
high standards
|
|
gptkbp:social_responsibility
|
gptkb:healthcare_access
|
|
gptkbp:stock_symbol
|
601607
|
|
gptkbp:subsidiary
|
Sinopharm Vaccine Technology Co., Ltd.
|
|
gptkbp:supply_chain
|
efficient logistics
pharmaceutical products
|
|
gptkbp:sustainability_practices
|
environmental responsibility
|
|
gptkbp:training
|
continuous development
|
|
gptkbp:treatment
|
monitored regularly
|
|
gptkbp:website
|
www.sinopharm.com
|
|
gptkbp:bfsParent
|
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:bfsLayer
|
5
|